trending Market Intelligence /marketintelligence/en/news-insights/trending/2Zv0nV9CL09OzRArmCpDxg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Aclaris Therapeutics prices $75M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aclaris Therapeutics prices $75M common stock offering

Aclaris Therapeutics Inc. priced an underwritten public offering of 3,260,000 common shares at $23.02 apiece, for expected gross proceeds of $75 million.

The company also granted underwriters a 30-day option to buy up to an additional 489,000 common shares at the public offering price.

The offering is expected to close on or around Aug. 16, subject to customary closing conditions.

Aclaris expects net proceeds of $70.3 million, after underwriting discounts, commissions and estimated offering expenses.

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering, with William Blair & Co. LLC, Guggenheim Securities LLC and JMP Securities LLC as co-managers.